Endo International (NASDAQ:ENDP) Downgraded by Royal Bank of Canada

Royal Bank of Canada downgraded shares of Endo International (NASDAQ:ENDP) (TSE:ENL) from an outperform rating to a sector perform rating in a research report released on Thursday morning, 24/7 WallStreet reports. Royal Bank of Canada currently has $6.00 price objective on the stock, down from their previous price objective of $11.00.

Several other equities research analysts have also recently issued reports on the company. Mizuho set a $9.00 price objective on Endo International and gave the stock a hold rating in a report on Tuesday, May 14th. SunTrust Banks assumed coverage on Zoetis in a report on Tuesday, March 19th. They set a hold rating and a $100.00 price objective on the stock. JPMorgan Chase & Co. raised their price objective on Vermilion Energy from C$42.00 to C$43.00 in a report on Monday, May 13th. Citigroup decreased their price objective on Thor Industries from $78.00 to $70.00 in a report on Monday, June 17th. Finally, ValuEngine cut Zynerba Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, May 28th. Three investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the company. The stock presently has an average rating of Hold and a consensus target price of $11.57.

ENDP stock opened at $4.10 on Thursday. Endo International has a 52-week low of $3.54 and a 52-week high of $18.50. The business’s fifty day simple moving average is $4.56. The firm has a market capitalization of $927.35 million, a PE ratio of 1.49 and a beta of 1.15.

Endo International (NASDAQ:ENDP) (TSE:ENL) last posted its quarterly earnings data on Thursday, May 9th. The company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.11. Endo International had a negative return on equity of 199.18% and a negative net margin of 18.35%. The business had revenue of $720.00 million for the quarter, compared to analysts’ expectations of $692.31 million. During the same quarter last year, the firm earned $0.67 earnings per share. The business’s revenue was up 2.9% on a year-over-year basis. Equities research analysts anticipate that Endo International will post 2.17 earnings per share for the current fiscal year.

In related news, Director Roger H. Kimmel sold 34,951 shares of Endo International stock in a transaction on Monday, June 17th. The stock was sold at an average price of $3.93, for a total value of $137,357.43. Following the transaction, the director now owns 148,309 shares in the company, valued at $582,854.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.80% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of ENDP. Signition LP acquired a new position in shares of Endo International during the first quarter worth about $139,000. Neuburgh Advisers LLC lifted its stake in shares of Endo International by 13.9% during the fourth quarter. Neuburgh Advisers LLC now owns 24,860 shares of the company’s stock worth $181,000 after purchasing an additional 3,036 shares in the last quarter. Factorial Partners LLC acquired a new position in shares of Endo International during the first quarter worth about $193,000. First Quadrant L P CA lifted its stake in shares of Endo International by 94.7% during the first quarter. First Quadrant L P CA now owns 24,513 shares of the company’s stock worth $197,000 after purchasing an additional 11,926 shares in the last quarter. Finally, Flinton Capital Management LLC lifted its stake in shares of Endo International by 13.9% during the fourth quarter. Flinton Capital Management LLC now owns 38,420 shares of the company’s stock worth $280,000 after purchasing an additional 4,692 shares in the last quarter. Institutional investors own 93.59% of the company’s stock.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Featured Article: How is Preferred Stock Different from Common Stock?

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.